Abbott Laboratories (NYSE:ABT) Stock Holdings Boosted by Andra AP fonden

Andra AP fonden boosted its position in Abbott Laboratories (NYSE:ABT) by 19.8% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 83,408 shares of the healthcare product maker’s stock after purchasing an additional 13,800 shares during the quarter. Andra AP fonden’s holdings in Abbott Laboratories were worth $9,434,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of ABT. Groupama Asset Managment boosted its position in shares of Abbott Laboratories by 22.2% during the third quarter. Groupama Asset Managment now owns 228,448 shares of the healthcare product maker’s stock worth $26,000 after buying an additional 41,557 shares during the period. Noble Wealth Management PBC bought a new stake in Abbott Laboratories during the 4th quarter valued at $26,000. NewSquare Capital LLC boosted its position in Abbott Laboratories by 78.4% during the 4th quarter. NewSquare Capital LLC now owns 239 shares of the healthcare product maker’s stock worth $27,000 after acquiring an additional 105 shares during the period. Peterson Financial Group Inc. bought a new position in shares of Abbott Laboratories in the third quarter worth $32,000. Finally, Wingate Wealth Advisors Inc. acquired a new position in shares of Abbott Laboratories during the fourth quarter valued at $34,000. 75.18% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, EVP Daniel Gesua Sive Salvadori sold 23,771 shares of the stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $128.50, for a total transaction of $3,054,573.50. Following the transaction, the executive vice president now owns 125,697 shares in the company, valued at $16,152,064.50. This represents a 15.90 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Lisa D. Earnhardt sold 91,167 shares of the stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $133.82, for a total transaction of $12,199,967.94. Following the transaction, the executive vice president now directly owns 71,928 shares in the company, valued at $9,625,404.96. The trade was a 55.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 116,449 shares of company stock worth $15,463,316. 1.10% of the stock is owned by company insiders.

Abbott Laboratories Trading Up 1.6 %

Abbott Laboratories stock opened at $137.23 on Friday. Abbott Laboratories has a 52 week low of $99.71 and a 52 week high of $141.23. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.14 and a current ratio of 1.60. The firm has a market capitalization of $238.00 billion, a price-to-earnings ratio of 17.94, a P/E/G ratio of 2.52 and a beta of 0.70. The company has a 50 day moving average price of $125.35 and a 200 day moving average price of $118.76.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Wednesday, January 22nd. The healthcare product maker reported $1.34 EPS for the quarter, hitting the consensus estimate of $1.34. The business had revenue of $10.97 billion during the quarter, compared to analysts’ expectations of $11.03 billion. Abbott Laboratories had a return on equity of 20.74% and a net margin of 31.95%. Abbott Laboratories’s revenue was up 7.2% compared to the same quarter last year. During the same quarter last year, the firm posted $1.19 earnings per share. Research analysts forecast that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, May 15th. Stockholders of record on Tuesday, April 15th will be issued a $0.59 dividend. The ex-dividend date is Tuesday, April 15th. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.72%. Abbott Laboratories’s dividend payout ratio is 30.85%.

Analysts Set New Price Targets

Several equities analysts have commented on ABT shares. Wells Fargo & Company raised their target price on shares of Abbott Laboratories from $133.00 to $136.00 and gave the company an “overweight” rating in a research note on Thursday, January 23rd. Barclays reissued an “overweight” rating and set a $158.00 target price (up previously from $149.00) on shares of Abbott Laboratories in a report on Monday, January 27th. Evercore ISI increased their price target on Abbott Laboratories to $136.00 and gave the company a “buy” rating in a research note on Thursday, January 2nd. Argus raised Abbott Laboratories to a “strong-buy” rating in a research note on Tuesday, January 28th. Finally, The Goldman Sachs Group upped their price objective on Abbott Laboratories from $138.00 to $154.00 and gave the company a “buy” rating in a report on Tuesday, March 4th. Four analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Abbott Laboratories presently has a consensus rating of “Moderate Buy” and a consensus target price of $137.19.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.